MME and heart failure: The second is sacubitril/valsartan, which is a 1:1 cocrystal between sacubitril sodium, a neprilysin (NEP) inhibitor, and valsartan sodium, an angiotensin receptor 1 (AT1) blocker (Entresto® Tablet; Novartis); it was approved by the FDA and the European Medicines Agency (EMA) in 2015 for the treatment of long-term heart failure in adult population.